Moore Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moore Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.29M	Sell	157,132 -42,868	-21%	-$965K	0.07%	215
2025 Q4	$4.6M	Sell	200,000 -70,000	-26%	-$2.3M	0.07%	266
2025 Q3	$8.12M	Sell	270,000 -20,000	-7%	-$600K	0.11%	170
2025 Q2	$10.5M	Buy	290,000 +50,000	+21%	+$1.8M	0.13%	133
2025 Q1	$8.69M	Sell	240,000 -5,000	-2%	-$208K	0.18%	122
2024 Q4	$10.3M	Hold	245,000	–	–	0.12%	172
2024 Q3	$13.6M	Hold	245,000	–	–	0.25%	117
2024 Q2	$10.1M	Buy	245,000 +60,000	+32%	+$2.56M	0.17%	134
2024 Q1	$8.64M	Hold	185,000	–	–	0.14%	138
2023 Q4	$8.85M	Buy	185,000 +35,000	+23%	+$1.36M	0.15%	106
2023 Q3	$5.35M	Buy	150,000 +45,000	+43%	+$1.78M	0.1%	150
2023 Q2	$4.84M	Buy	105,000 +75,000	+250%	+$3.48M	0.08%	173
2023 Q1	$1.2M	Buy	+30,000	New	+$1.29M	0.03%	280
2016 Q1	–	Sell	-32,000	Closed	-$3.59M	–	326
2015 Q4	$3.59M	Buy	+32,000	New	+$3.2M	0.11%	158
2015 Q2	–	Sell	-35,000	Closed	-$2.17M	–	500
2015 Q1	$2.17M	Buy	+35,000	New	+$1.94M	0.05%	264

Other funds holding RARE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Moore Capital Management's RARE Position: Q1 2026 in Review

Moore Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 21% in Q1 2026, selling an estimated $965K and leaving 157,132 shares worth $3.29M. The position accounts for 0.07% of the portfolio, ranked #215.

Moore Capital Management first reported a position in RARE in Q1 2015 and has held it in 15 quarters since. The position peaked at $13.6M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Moore Capital Management held 157,132 shares of Ultragenyx Pharmaceutical worth $3.29M as of Q1 2026.
Moore Capital Management sold 42,868 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $965K.
Ultragenyx Pharmaceutical made up 0.07% of Moore Capital Management's portfolio in Q1 2026, its #215 holding.
Moore Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 15 quarters since.
Moore Capital Management's Ultragenyx Pharmaceutical position peaked at $13.6M in Q3 2024.
295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.